Published in J Infect Dis on January 17, 2013
Robust and Balanced Immune Responses to All 4 Dengue Virus Serotypes Following Administration of a Single Dose of a Live Attenuated Tetravalent Dengue Vaccine to Healthy, Flavivirus-Naive Adults. J Infect Dis (2015) 1.72
Safety and immunogenicity of a recombinant live attenuated tetravalent dengue vaccine (DENVax) in flavivirus-naive healthy adults in Colombia: a randomised, placebo-controlled, phase 1 study. Lancet Infect Dis (2014) 1.67
The dengue vaccine pipeline: Implications for the future of dengue control. Vaccine (2015) 1.28
Human monoclonal antibodies derived from memory B cells following live attenuated dengue virus vaccination or natural infection exhibit similar characteristics. J Infect Dis (2013) 1.16
New insights into the immunopathology and control of dengue virus infection. Nat Rev Immunol (2015) 1.10
Analyzing the development of vaccines for flavivirus-endemic scenarios: the case of Dengue and Dengue vaccine in Peru. J Infect Dis (2013) 1.08
The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes. J Virol (2014) 1.08
Dengue vaccines: recent developments, ongoing challenges and current candidates. Expert Rev Vaccines (2013) 0.94
Vaccination of volunteers with low-dose, live-attenuated, dengue viruses leads to serotype-specific immunologic and virologic profiles. Vaccine (2013) 0.94
The burden of dengue and chikungunya worldwide: implications for the southern United States and California. Ann Glob Health (2015) 0.93
An adjuvanted, tetravalent dengue virus purified inactivated vaccine candidate induces long-lasting and protective antibody responses against dengue challenge in rhesus macaques. Am J Trop Med Hyg (2015) 0.93
Guiding dengue vaccine development using knowledge gained from the success of the yellow fever vaccine. Cell Mol Immunol (2015) 0.92
The live attenuated chimeric vaccine rWN/DEN4Δ30 is well-tolerated and immunogenic in healthy flavivirus-naïve adult volunteers. Vaccine (2013) 0.89
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine? Expert Rev Vaccines (2015) 0.87
Utility, limitations, and future of non-human primates for dengue research and vaccine development. Front Immunol (2014) 0.86
Live virus vaccines based on a yellow fever vaccine backbone: standardized template with key considerations for a risk/benefit assessment. Vaccine (2014) 0.84
Japanese encephalitis virus vaccine candidates generated by chimerization with dengue virus type 4. Vaccine (2014) 0.82
A 12-Month-Interval Dosing Study in Adults Indicates That a Single Dose of the National Institute of Allergy and Infectious Diseases Tetravalent Dengue Vaccine Induces a Robust Neutralizing Antibody Response. J Infect Dis (2016) 0.82
Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial. J Infect Dis (2015) 0.79
Dengue vaccines: strongly sought but not a reality just yet. PLoS Pathog (2013) 0.77
Human CD4+ T cell responses to an attenuated tetravalent dengue vaccine parallel those induced by natural infection, in magnitude, HLA restriction and antigen specificity. J Virol (2016) 0.77
Induction of neutralizing antibodies against four serotypes of dengue viruses by MixBiEDIII, a tetravalent dengue vaccine. PLoS One (2014) 0.77
Induction of neutralizing antibody response against four dengue viruses in mice by intramuscular electroporation of tetravalent DNA vaccines. PLoS One (2014) 0.76
Vaccines and immunization strategies for dengue prevention. Emerg Microbes Infect (2016) 0.76
Dengue vaccines: what we know, what has been done, but what does the future hold? Rev Saude Publica (2015) 0.76
Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity. Microbiol Mol Biol Rev (2016) 0.75
Evaluation of protection induced by a dengue virus serotype 2 envelope domain III protein scaffold/DNA vaccine in non-human primates. Vaccine (2016) 0.75
Prospects for dengue vaccines for travelers. Clin Exp Vaccine Res (2016) 0.75
Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination. J Virol (2014) 0.75
Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain. J Virol (2017) 0.75
Economic Burden of Dengue Virus Infection at the Household Level Among Residents of Puerto Maldonado, Peru. Am J Trop Med Hyg (2015) 0.75
Response to Ruiz-Alejo et al. J Infect Dis (2013) 0.75
Potent Plasmablast-Derived Antibodies Elicited by the NIH Dengue Vaccine. J Virol (2017) 0.75
Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet (2012) 12.41
Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity. J Infect Dis (2000) 11.44
Dengue. N Engl J Med (2012) 10.45
Research on dengue during World War II. Am J Trop Med Hyg (1952) 8.76
A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg (1988) 8.54
Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study. Am J Trop Med Hyg (1990) 3.41
Impact of dengue/dengue hemorrhagic fever on the developing world. Adv Virus Res (1999) 3.29
Dengue haemorrhagic fever/dengue shock syndrome: lessons from the Cuban epidemic, 1981. Bull World Health Organ (1989) 2.90
Attenuation and immunogenicity in humans of a live dengue virus type-4 vaccine candidate with a 30 nucleotide deletion in its 3'-untranslated region. Am J Trop Med Hyg (2001) 2.67
Why dengue haemorrhagic fever in Cuba? 1. Individual risk factors for dengue haemorrhagic fever/dengue shock syndrome (DHF/DSS). Trans R Soc Trop Med Hyg (1987) 2.48
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46
Best practices in dengue surveillance: a report from the Asia-Pacific and Americas Dengue Prevention Boards. PLoS Negl Trop Dis (2010) 2.45
Haiti: absence of dengue hemorrhagic fever despite hyperendemic dengue virus transmission. Am J Trop Med Hyg (2001) 2.35
Analysis of repeat hospital admissions for dengue to estimate the frequency of third or fourth dengue infections resulting in admissions and dengue hemorrhagic fever, and serotype sequences. Am J Trop Med Hyg (2007) 2.06
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults. J Infect Dis (2010) 1.96
Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine. Am J Trop Med Hyg (2003) 1.65
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults. Hum Vaccin (2009) 1.61
Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine (2011) 1.53
Evaluation of interferences between dengue vaccine serotypes in a monkey model. Am J Trop Med Hyg (2009) 1.45
Antibody responses to Haemophilus influenzae type b polysaccharide vaccine in relation to Km(1) and G2m(23) immunoglobulin allotypes. J Infect Dis (1986) 1.43
The burden of dengue infection. Lancet (2007) 1.41
Antibody to dengue 1 detected more than 60 years after infection. Viral Immunol (2007) 1.38
Live-attenuated Tetravalent Dengue Vaccine in Dengue-naïve Children, Adolescents, and Adults in Mexico City: Randomized Controlled Phase 1 Trial of Safety and Immunogenicity. Pediatr Infect Dis J (2011) 1.37
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine. Vaccine (2011) 1.36
rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults. Hum Vaccin (2006) 1.36
The live attenuated dengue serotype 1 vaccine rDEN1Delta30 is safe and highly immunogenic in healthy adult volunteers. Hum Vaccin (2006) 1.35
Immunological and viral determinants of dengue severity in hospitalized adults in Ha Noi, Viet Nam. PLoS Negl Trop Dis (2011) 1.29
Phase I clinical evaluation of rDEN4Delta30-200,201: a live attenuated dengue 4 vaccine candidate designed for decreased hepatotoxicity. Am J Trop Med Hyg (2008) 1.28
Demographic factors that influence the neutralizing antibody response in recipients of recombinant HIV-1 gp120 vaccines. J Infect Dis (2004) 1.28
Infections with two dengue viruses in Greece in the 20th century. Did dengue hemorrhagic fever occur in the 1928 epidemic? J Trop Med Hyg (1977) 1.19
Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis (2011) 1.11
Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol (2009) 1.08
Genetic ancestry and income are associated with dengue hemorrhagic fever in a highly admixed population. Eur J Hum Genet (2008) 1.07
A single dose of the DENV-1 candidate vaccine rDEN1Δ30 is strongly immunogenic and induces resistance to a second dose in a randomized trial. PLoS Negl Trop Dis (2011) 1.04
Host and viral factors affecting the decreased immunogenicity of Sabin type 3 vaccine after administration of trivalent oral polio vaccine to rural Mayan children. J Infect Dis (1997) 1.03
Cost of production of live attenuated dengue vaccines: a case study of the Instituto Butantan, Sao Paulo, Brazil. Vaccine (2012) 1.01
Heterotypic dengue infection with live attenuated monotypic dengue virus vaccines: implications for vaccination of populations in areas where dengue is endemic. J Infect Dis (2010) 1.00
The association of ethnicity with antibody responses to pneumococcal vaccination among adults with HIV infection. Vaccine (2010) 0.84
Oral immunization against poliomyelitis. Bull World Health Organ (1960) 0.82
Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med (2011) 7.29
Lack of transmission of H5N1 avian-human reassortant influenza viruses in a ferret model. Proc Natl Acad Sci U S A (2006) 6.35
Systems biology of vaccination for seasonal influenza in humans. Nat Immunol (2011) 6.09
Prospects for a dengue virus vaccine. Nat Rev Microbiol (2007) 4.99
An efficient method to make human monoclonal antibodies from memory B cells: potent neutralization of SARS coronavirus. Nat Med (2004) 4.89
Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J Clin Invest (2010) 4.62
A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice. Nature (2004) 3.90
Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis (2005) 3.79
Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets. PLoS Med (2006) 3.71
Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza. PLoS Med (2007) 3.63
The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe (2010) 3.48
pH-dependent entry of severe acute respiratory syndrome coronavirus is mediated by the spike glycoprotein and enhanced by dendritic cell transfer through DC-SIGN. J Virol (2004) 3.04
A mouse-adapted SARS-coronavirus causes disease and mortality in BALB/c mice. PLoS Pathog (2007) 2.71
Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PLoS One (2008) 2.70
Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol (2011) 2.68
Genetic diversity between human metapneumovirus subgroups. Virology (2003) 2.65
Antigenic fingerprinting of H5N1 avian influenza using convalescent sera and monoclonal antibodies reveals potential vaccine and diagnostic targets. PLoS Med (2009) 2.47
rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers. J Infect Dis (2005) 2.46
Development of effective vaccines against pandemic influenza. Immunity (2006) 2.45
Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proc Natl Acad Sci U S A (2004) 2.38
Identification and characterization of severe acute respiratory syndrome coronavirus replicase proteins. J Virol (2004) 2.38
Prospective case-control study of the association between common enteric protozoal parasites and diarrhea in Bangladesh. Clin Infect Dis (2009) 2.35
Neuraminidase stalk length and additional glycosylation of the hemagglutinin influence the virulence of influenza H5N1 viruses for mice. J Virol (2009) 2.32
Pause on avian flu transmission research. Science (2012) 2.24
Anatomical loci of HIV-associated immune activation and association with viraemia. Lancet (2003) 2.19
Successful topical respiratory tract immunization of primates against Ebola virus. J Virol (2007) 2.06
Recombinant human Metapneumovirus lacking the small hydrophobic SH and/or attachment G glycoprotein: deletion of G yields a promising vaccine candidate. J Virol (2004) 2.03
The two major human metapneumovirus genetic lineages are highly related antigenically, and the fusion (F) protein is a major contributor to this antigenic relatedness. J Virol (2004) 2.02
Maturation of West Nile virus modulates sensitivity to antibody-mediated neutralization. PLoS Pathog (2008) 2.00
Epidemiologic and clinical characteristics of acute diarrhea with emphasis on Entamoeba histolytica infections in preschool children in an urban slum of Dhaka, Bangladesh. Am J Trop Med Hyg (2003) 1.92
Replication of SARS coronavirus administered into the respiratory tract of African Green, rhesus and cynomolgus monkeys. Virology (2004) 1.91
DNA vaccine expressing conserved influenza virus proteins protective against H5N1 challenge infection in mice. Emerg Infect Dis (2002) 1.88
Eurasian-origin gene segments contribute to the transmissibility, aerosol release, and morphology of the 2009 pandemic H1N1 influenza virus. PLoS Pathog (2011) 1.87
Recovery of human metapneumovirus from cDNA: optimization of growth in vitro and expression of additional genes. Virology (2004) 1.81
The novel oral typhoid vaccine M01ZH09 is well tolerated and highly immunogenic in 2 vaccine presentations. J Infect Dis (2005) 1.81
Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans. J Virol (2005) 1.79
Polygenic virulence factors involved in pathogenesis of 1997 Hong Kong H5N1 influenza viruses in mice. Virus Res (2007) 1.77
Potent cross-reactive neutralization of SARS coronavirus isolates by human monoclonal antibodies. Proc Natl Acad Sci U S A (2007) 1.76
Evaluation of replication and pathogenicity of avian influenza a H7 subtype viruses in a mouse model. J Virol (2007) 1.76
Severe acute respiratory syndrome coronavirus infection of golden Syrian hamsters. J Virol (2005) 1.75
Long-term protection from SARS coronavirus infection conferred by a single immunization with an attenuated VSV-based vaccine. Virology (2005) 1.74
Engineering H5N1 avian influenza viruses to study human adaptation. Nature (2012) 1.74
Recombinant newcastle disease virus expressing a foreign viral antigen is attenuated and highly immunogenic in primates. J Virol (2005) 1.72
Attribution of malnutrition to cause-specific diarrheal illness: evidence from a prospective study of preschool children in Mirpur, Dhaka, Bangladesh. Am J Trop Med Hyg (2009) 1.71
A dynamic landscape for antibody binding modulates antibody-mediated neutralization of West Nile virus. PLoS Pathog (2011) 1.70
Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. Proc Natl Acad Sci U S A (2004) 1.69
The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines. Vaccine (2007) 1.68
The Immunobiology of SARS*. Annu Rev Immunol (2007) 1.61
Temperature-dependent production of pseudoinfectious dengue reporter virus particles by complementation. Virology (2008) 1.60
New generation live vaccines against human respiratory syncytial virus designed by reverse genetics. Proc Am Thorac Soc (2005) 1.58
A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. J Virol (2006) 1.58
Reappearance and global spread of variants of influenza B/Victoria/2/87 lineage viruses in the 2000-2001 and 2001-2002 seasons. Virology (2002) 1.57
A single-amino-acid substitution in a polymerase protein of an H5N1 influenza virus is associated with systemic infection and impaired T-cell activation in mice. J Virol (2009) 1.56
A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a Phase I trial in healthy adults. Vaccine (2009) 1.56
Dengue vaccine candidates in development. Curr Top Microbiol Immunol (2010) 1.56
Multistate outbreak of Listeria monocytogenes infection linked to delicatessen turkey meat. Clin Infect Dis (2005) 1.55
Genetic basis of attenuation of dengue virus type 4 small plaque mutants with restricted replication in suckling mice and in SCID mice transplanted with human liver cells. Virology (2002) 1.55
FDA/NIH/WHO public workshop on immune correlates of protection against influenza A viruses in support of pandemic vaccine development, Bethesda, Maryland, US, December 10-11, 2007. Vaccine (2008) 1.55
Phenotyping of peripheral blood mononuclear cells during acute dengue illness demonstrates infection and increased activation of monocytes in severe cases compared to classic dengue fever. Virology (2008) 1.54
Evaluation of human monoclonal antibody 80R for immunoprophylaxis of severe acute respiratory syndrome by an animal study, epitope mapping, and analysis of spike variants. J Virol (2005) 1.54
Nonsegmented negative-strand viruses as vaccine vectors. J Virol (2006) 1.53
Emerging respiratory viruses: challenges and vaccine strategies. Clin Microbiol Rev (2006) 1.52
A trade-off in replication in mosquito versus mammalian systems conferred by a point mutation in the NS4B protein of dengue virus type 4. Virology (2003) 1.51
Evaluation of two live attenuated cold-adapted H5N1 influenza virus vaccines in healthy adults. Vaccine (2009) 1.51
A severe acute respiratory syndrome coronavirus that lacks the E gene is attenuated in vitro and in vivo. J Virol (2006) 1.51
Respiratory syncytial virus: reverse genetics and vaccine strategies. Virology (2002) 1.51
Global TravEpiNet: a national consortium of clinics providing care to international travelers--analysis of demographic characteristics, travel destinations, and pretravel healthcare of high-risk US international travelers, 2009-2011. Clin Infect Dis (2011) 1.51
Animal models and vaccines for SARS-CoV infection. Virus Res (2007) 1.50
A live, attenuated dengue virus type 1 vaccine candidate with a 30-nucleotide deletion in the 3' untranslated region is highly attenuated and immunogenic in monkeys. J Virol (2003) 1.50
Attacking the flu: neutralizing antibodies may lead to 'universal' vaccine. Nat Med (2009) 1.49
A live attenuated cold-adapted influenza A H7N3 virus vaccine provides protection against homologous and heterologous H7 viruses in mice and ferrets. Virology (2008) 1.48
Generation and evaluation of a high-growth reassortant H9N2 influenza A virus as a pandemic vaccine candidate. Vaccine (2003) 1.48
Innovative surveillance methods for rapid detection of disease outbreaks and bioterrorism: results of an interagency workshop on health indicator surveillance. Am J Public Health (2003) 1.46
Borrelia burgdorferi infection in a natural population of Peromyscus Leucopus mice: a longitudinal study in an area where Lyme Borreliosis is highly endemic. J Infect Dis (2004) 1.46
Entamoeba histolytica-associated diarrheal illness is negatively associated with the growth of preschool children: evidence from a prospective study. Trans R Soc Trop Med Hyg (2006) 1.45
Mechanisms of host defense following severe acute respiratory syndrome-coronavirus (SARS-CoV) pulmonary infection of mice. J Immunol (2004) 1.45
Development of a live attenuated dengue virus vaccine using reverse genetics. Viral Immunol (2006) 1.44
Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice. J Infect Dis (2005) 1.44